Remove 2011 Remove Documentation Remove Pharmaceutical Companies
article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. Having worked for CROs since graduating, Sophie joined Pfizer in 2011 and has had various roles within the UK and now global groups.

article thumbnail

Case Study 3 – Expert Regulatory Affairs Services for a European-Based Client

Impact Pharmaceutical Services

In 2011, following referral from another company, IMPACT (now part of Syner-G BioPharma Group) was contacted by a small development stage pharmaceutical company located in the United Kingdom to assist them with pre-IND activities for a new chemical entity for the treatment of asthma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

Even though patients are on existing [statins] that are well-documented and most likely safe and effective, there are many patients who still have cardiovascular disease, the leading cause of death” We are recognising now is that there is great data on how to reduce risk by applying lipid lowering therapy like statins.

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

There was bipartisan support for the program at the hearing and support for measures such as requiring pharmaceutical companies to publish their prices in a password protected site on HRSA's website. Also, in 2011, the U.S. 2006: Congress passed, and President George W. 340B providers expressed significant concern.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 The prerequisite to present statistically significant evidence for having efficacies of clinical relevance is crucial because FDA requires “adequate and well-controlled” multicentre clinical studies on any new drug candidate to document and support its safety and efficacy, and imposes the maximum level of scrutiny prior to approval.

FDA 103
article thumbnail

ICH Q13 and What Is Next for Continuous Manufacturing

ISPE

1 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q13 Development Timeline The process of drafting the new guidance document was initiated in earnest in November 2018 when the concept paper 2 and business plan were endorsed.

article thumbnail

A Systemwide Approach to Managing the Risks of Continuous Manufacturing

ISPE

NASA Risk Management Handbook NASA/SP-2011-3422, Version 1.0. NASA Headquarters, 2011. link] The SRM risk assessment process is only as strong as the underlying risk culture and governance practices of the company. One of the most important components of SRM is the company’s risk appetite statement. 17 (2011): 10083–92.